Ertugliflozin 5 and 15 mg treatment for 26 weeks provides effective glycaemic control, reduces body weight and is generally well tolerated, when used as monotherapy.

ClinicalTrials identifier: NCT00788944.

ClinicalTrials.gov identifier: NCT01121484.

In contrast to venlafaxine ER 75  mg, the pharmacokinetics of desvenlafaxine 50  mg is not significantly impacted by CYP2D6 genetic polymorphisms. PMs receiving venlafaxine ER 75  mg had significantly lower O-desmethylvenlafaxine and higher venlafaxine plasma concentrations.

ClinicalTrials.gov identifier: NCT01432457.